VPR Brands Announces Favorable Settlement of Second Patent Infringement Case
06 janv. 2022 08h00 HE
|
VPR Brands LP
FORT LAUDERDALE, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- VPR Brands, LP (OTC: VPRB): VPR Brands is a market leader and pioneer in electronic cigarettes and vaporizers for nicotine, cannabis and...
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation
04 janv. 2022 08h30 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
22nd Century Ready to Provide Full Commercial Support to New Zealand’s Plan to Reduce Nicotine Content of All Cigarettes
10 déc. 2021 09h20 HE
|
22nd Century Group, Inc
New Zealand Ministry of Health announced aggressive measures to reduce smoking, including a reduced nicotine mandate by 2025 22nd Century fully engaged and ready to support New Zealand’s government...
Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation
23 nov. 2021 08h30 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)
22 nov. 2021 08h30 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development
09 nov. 2021 16h05 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 09, 2021 (GLOBE NEWSWIRE) -- -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leader in Emerging Psychedelic-Assisted Psychotherapy Industry
04 nov. 2021 08h30 HE
|
Mydecine Innovations Group Inc.
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announces the availability of a broadcast titled, “Breaking the Habit:...
Achieve Life Sciences Announces Participation in November Investor Conferences
04 nov. 2021 08h30 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline’s Second Planned Indication for Nicotine E-cigarette Cessation
02 nov. 2021 08h30 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Part of Psychedelic Medicine Research Renaissance
02 nov. 2021 08h30 HE
|
Mydecine Innovations Group Inc.
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) today announces its placement in an editorial published by...